Sacubitril/Valsartan

What is Sacubitril/Valsartan?

Sacubitril Valsartan is a prescription medication primarily used to treat chronic heart failure with reduced ejection fraction. It is a combination drug, meaning it contains two active ingredients: sacubitril and valsartan. Marketed under the brand name Entresto, this medication belongs to a class of drugs known as angiotensin receptor-neprilysin inhibitors (ARNIs). It is designed to help the heart pump blood more efficiently, reduce symptoms associated with heart failure, and improve the overall quality of life for patients.

Sacubitril Valsartan represents a significant advancement in the management of heart failure, offering a dual mechanism of action that targets key pathways involved in the progression of the disease. Its introduction has provided a new and effective option for patients who may not have adequately responded to or tolerated other standard therapies.

How Does it Work?

The effectiveness of Sacubitril Valsartan stems from its unique dual mechanism of action, combining the benefits of two distinct pharmacological agents:

• Sacubitril: This component is a neprilysin inhibitor. Neprilysin is an enzyme that breaks down natural natriuretic peptides (NPs) in the body. By inhibiting neprilysin, sacubitril increases the levels of these beneficial peptides. Natriuretic peptides help to lower blood pressure, reduce fluid retention, and decrease the workload on the heart, ultimately improving cardiovascular function.
• Valsartan: This component is an angiotensin receptor blocker (ARB). Valsartan works by blocking the effects of angiotensin II, a powerful hormone that narrows blood vessels, increases blood pressure, and promotes fluid retention. By blocking angiotensin II receptors, valsartan helps to relax blood vessels, lower blood pressure, and reduce the strain on the heart.

Together, these two mechanisms provide a synergistic effect. The ARNI class of drugs, which includes Sacubitril Valsartan, aims to enhance the body's protective neurohormonal systems (via sacubitril) while simultaneously inhibiting the detrimental effects of the renin-angiotensin-aldosterone system (via valsartan). This dual action leads to improved cardiac function, reduced hospitalizations for heart failure, and a decrease in cardiovascular mortality.

Medical Uses

Sacubitril Valsartan is primarily indicated for:

• Chronic Heart Failure with Reduced Ejection Fraction (HFrEF): This is the most common and well-established use. It is prescribed for adult patients to reduce the risk of cardiovascular death and hospitalization for heart failure. It is often used in place of an ACE inhibitor or another ARB in patients who are symptomatic despite optimal medical therapy.
• Symptomatic Chronic Heart Failure in Pediatric Patients: In certain cases, it may also be used in pediatric patients aged one year and older with symptomatic chronic heart failure with systemic left ventricular systolic dysfunction.

The decision to prescribe Sacubitril Valsartan is typically made by a cardiologist or healthcare provider specializing in heart conditions, after a thorough evaluation of the patient's specific type and severity of heart failure, as well as their overall health profile.

Dosage

The dosage of Sacubitril Valsartan must be individualized based on the patient's clinical response and tolerability. It is available in different strengths, typically expressed as the total amount of sacubitril and valsartan combined (e.g., 24/26 mg, 49/51 mg, 97/103 mg). The medication is taken orally, usually twice daily.

Typical Dosing Schedule:

• Initial Dose: For adults, a common starting dose is 49/51 mg twice daily. However, for patients not currently taking an ACE inhibitor or ARB, or those with severe renal impairment or liver impairment, a lower starting dose (e.g., 24/26 mg twice daily) may be recommended.
• Titration: The dose is typically doubled every 2 to 4 weeks, as tolerated, until the target maintenance dose of 97/103 mg twice daily is reached.
• Monitoring: During dose titration and maintenance, blood pressure, kidney function, and serum potassium levels should be regularly monitored.

It is crucial for patients to follow their doctor's instructions precisely and not to adjust the dose or stop taking the medication without consulting their healthcare provider. Missing doses or discontinuing the drug abruptly can worsen heart failure symptoms.

Side Effects

Like all medications, Sacubitril Valsartan can cause side effects. Some are common and mild, while others can be serious.

Common Side Effects:

• Low blood pressure (hypotension)
• High potassium levels (hyperkalemia)
• Cough
• Dizziness or lightheadedness
• Kidney problems (renal impairment)
• Fatigue
• Nausea

Serious Side Effects (Seek immediate medical attention if experienced):

• Angioedema: Swelling of the face, lips, tongue, or throat, which can make breathing difficult. This is a rare but potentially life-threatening reaction. It is more common in patients with a history of angioedema.
• Severe Low Blood Pressure: Especially in patients who are dehydrated or have severe heart failure.
• Worsening Kidney Function: Particularly in patients with pre-existing kidney disease.
• High Potassium Levels: Which can lead to dangerous heart rhythm abnormalities.

Patients should report any new or worsening symptoms to their doctor promptly.

Drug Interactions

Sacubitril Valsartan can interact with other medications, potentially altering their effects or increasing the risk of side effects. Key drug interactions include:

• ACE Inhibitors: Concomitant use with ACE inhibitors is contraindicated. A washout period of at least 36 hours is required when switching from an ACE inhibitor to Sacubitril Valsartan, or vice versa, to reduce the risk of angioedema.
• Other Angiotensin Receptor Blockers (ARBs): Sacubitril Valsartan already contains valsartan, so it should not be used with other ARBs.
• Potassium-Sparing Diuretics, Potassium Supplements, or Salt Substitutes Containing Potassium: Co-administration can increase the risk of hyperkalemia.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Including selective COX-2 inhibitors, can increase the risk of kidney problems and reduce the blood pressure-lowering effect of Sacubitril Valsartan.
• Lithium: Concurrent use may increase lithium levels, leading to toxicity.
• Aliskiren: Should not be used with Sacubitril Valsartan in patients with diabetes or moderate to severe renal impairment.

Always inform your doctor and pharmacist about all medications you are taking, including over-the-counter drugs, herbal supplements, and vitamins, to avoid potential interactions.

FAQ

Is Sacubitril/Valsartan a cure for heart failure?

No, Sacubitril Valsartan is not a cure for heart failure. It is a treatment that helps manage symptoms, improve heart function, reduce hospitalizations, and extend life for patients with chronic heart failure.

How long does it take for Sacubitril/Valsartan to work?

While some patients may feel an improvement in symptoms within a few weeks, the full benefits of Sacubitril Valsartan, such as reduced risk of cardiovascular events, may take several months to become apparent. Consistent use as prescribed is key.

Can I stop taking Sacubitril/Valsartan if I feel better?

No, you should never stop taking Sacubitril Valsartan without consulting your doctor. Abruptly discontinuing the medication can lead to a worsening of heart failure symptoms and increase your risk of adverse events.

What is the difference between Sacubitril/Valsartan and an ACE inhibitor?

Both Sacubitril Valsartan and ACE inhibitors are used to treat heart failure. ACE inhibitors block the production of angiotensin II, while Sacubitril Valsartan blocks the effects of angiotensin II (via valsartan) and also enhances the body's protective natriuretic peptides (via sacubitril). This dual action makes Sacubitril Valsartan generally more effective for certain heart failure patients, but it cannot be used concurrently with an ACE inhibitor.

Products containing Sacubitril/Valsartan are available through trusted online pharmacies. You can browse Sacubitril/Valsartan-based medications at ShipperVIP or Medicenter.

Summary

Sacubitril Valsartan, commonly known as Entresto, represents a cornerstone in the modern management of chronic heart failure with reduced ejection fraction. Its innovative mechanism, combining an angiotensin receptor blocker with a neprilysin inhibitor, offers significant benefits in improving cardiac function, reducing symptoms, and lowering the risk of hospitalization and cardiovascular mortality. While generally well-tolerated, awareness of potential side effects and crucial drug interactions is essential for safe and effective use. As a powerful prescription medication, its use requires careful medical supervision, with individualized dosing and regular monitoring to ensure optimal outcomes for patients living with heart failure.